Galapagos NV
GLPGDrugs in Pipeline
15
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Filgotinib
Crohn's Disease
GLPG3667
Dermatomyositis
GLPG2222 50 mg
Cystic Fibrosis
GLPG1205
Idiopathic Pulmonary Fibrosis
GLPG3970
Rheumatoid Arthritis
GLPG1837 dose 1
Cystic Fibrosis
GLPG0974
Ulcerative Colitis
GLPG2222 150 mg q.d.
Cystic Fibrosis
GLPG1837 dose 2
Cystic Fibrosis
GLPG1690 600 mg QD
Idiopathic Pulmonary Fibrosis
GLPG0634
Rheumatoid Arthritis
GLPG1690
Systemic Sclerosis
GLPG1972
Osteoarthritis
GLPG2737
Cystic Fibrosis
GLPG0259 oral capsule
Rheumatoid Arthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Filgotinib | Phase 3 | Crohn's Disease | - | - |
GLPG3667 | Phase 2 | Dermatomyositis | - | - |
GLPG2222 50 mg | Phase 2 | Cystic Fibrosis | - | - |
GLPG1205 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
GLPG3970 | Phase 2 | Rheumatoid Arthritis | - | - |
GLPG1837 dose 1 | Phase 2 | Cystic Fibrosis | - | - |
GLPG0974 | Phase 2 | Ulcerative Colitis | - | - |
GLPG2222 150 mg q.d. | Phase 2 | Cystic Fibrosis | - | - |
GLPG1837 dose 2 | Phase 2 | Cystic Fibrosis | - | - |
GLPG1690 600 mg QD | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
GLPG0634 | Phase 2 | Rheumatoid Arthritis | - | - |
GLPG1690 | Phase 2 | Systemic Sclerosis | - | - |
GLPG1972 | Phase 2 | Osteoarthritis | - | - |
GLPG2737 | Phase 2 | Cystic Fibrosis | - | - |
GLPG0259 oral capsule | Phase 2 | Rheumatoid Arthritis | - | - |
Cystic Fibrosis
5 drugs in this indication
Rheumatoid Arthritis
4 drugs in this indication
Idiopathic Pulmonary Fibrosis
2 drugs in this indication
Dermatomyositis
1 drug in this indication
Ulcerative Colitis
1 drug in this indication
Crohn's Disease
1 drug in this indication
Systemic Sclerosis
1 drug in this indication
Osteoarthritis
1 drug in this indication
Ankylosing Spondylitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)